Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;329:51 (3 July), doi:10.1136/bmj.329.7456.51
| The first 150 words of the full text of this article appear below. |
EDITORWe learn with great concern that Medsafe [the New Zealand Medicines and Medical Devices Safety Authority], a part of your ministry, intends to stop funding the intensive medicines monitoring programme (IMMP) next year.
In its 27 years' work the IMMP has contributed very valuably to the safety of medicines in New Zealand and worldwide. Drug regulatory agencies in other countries and professionals working on the safety of medicines have admired and envied it because it has so successfully identified previously unrecognised adverse reactions, measured risks, and identified risk factors. For example, it enabled New Zealand to lead the world in taking regulatory action over agranulocytosis due to mianserin and liver toxicity due to nefazodone.1 2
Many drug disasters have shown that it is unsafe to rely only on spontaneous reporting of suspected adverse drug reactions. Such systems are essential, but the data they provide mostly suffer from gross under-reporting
Andrew Herxheimer, emeritus fellow
UK Cochrane Centre London N3 2NL andrew_herxheimer@compuserve.com
Read all Rapid Responses